<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330902</url>
  </required_header>
  <id_info>
    <org_study_id>SGS64</org_study_id>
    <nct_id>NCT00330902</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan</brief_title>
  <official_title>Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tropical Medicine Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In areas of seasonal malaria transmission, treatment of carriers of malaria parasites, whose
      parasitaemia persists at very low levels throughout the dry season, could be a useful
      strategy for malaria control in areas with a short transmission season. We did a randomized
      trial to compare two regimens for clearance of low level parasitaemia in the dry season.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      104 individuals with low density Plasmodium falciparum infection detected by polymerase chain
      reaction (PCR) were randomized to receive sulfadoxine-pyrimethamine and three daily doses of
      artesunate (SP+AS) or SP+AS and a dose of primaquine (SP+AS+PQ), and were followed up for 14
      days during the transmission-free season in Eastern Sudan. Subjects were visited on days 3, 7
      and 14 after the start of treatment to record any adverse events and to detect P.falciparum
      using PCR. PCR positive samples were tested for gametocytes using RT-PCR. Packed cell volume
      was measured on days 7 and 14.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>P.falciparum parasitaemia detected by PCR on days 3,7 and 14.</measure>
    <time_frame>14 days from start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of gametocytes detected by RT-PCR on days 3, 7 and 14.</measure>
    <time_frame>14 days from start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Packed Cell volume on days 7 and 14.</measure>
    <time_frame>Over 14 days from start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Plasmodium Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sulfadoxine pyrimethamine plus three daily doses of artesunate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sulfadoxine pyrimethamine plus artesunate plus primaquine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulfadoxine-pyrimethamine (SP) plus artesunate (AS)</intervention_name>
    <description>sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>primaquine (PQ) plus SP+AS</intervention_name>
    <description>single dose of primaquine on day 4</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infection with P.falciparum detected by PCR

        Exclusion Criteria:

          -  pregnancy

          -  severe anaemia

          -  fever or other signs of illness

          -  history of allergy to sulfa drugs

          -  presence of other species of Plasmodium detected by microscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Badria B El Sayed, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TMRI, Khartoum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omer Z Baraka, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, University of Khartoum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tropical Medicine Research Institute</name>
      <address>
        <city>Khartoum</city>
        <country>Sudan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2006</study_first_submitted>
  <study_first_submitted_qc>May 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2006</study_first_posted>
  <last_update_submitted>October 30, 2007</last_update_submitted>
  <last_update_submitted_qc>October 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2007</last_update_posted>
  <keyword>malaria</keyword>
  <keyword>subpatent parasitaemia</keyword>
  <keyword>dry season</keyword>
  <keyword>primaquine</keyword>
  <keyword>Plasmodium falciparum infection detected by PCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Parasitemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

